8-K filed Sep 15, 2026 at 06:45 ET
Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 Phase 3 trial in IgA nephropathy (IgAN). The drug demonstrated a 5.6 mL/min/1.73m2 placebo-adjusted difference in mean eGFR change at 52 weeks (p<0.0001), a 76% risk reduction in the composite kidney disease progression endpoint (HR 0.24, p<0.0001), and a favorable safety profile. The company plans to submit a supplemental BLA for full approval in Q4 2026, and reported strong commercial launch momentum with over 350 patient start forms generated in the first ten weeks. This is a transformative data readout that strongly supports the drug's disease-modifying potential and de-risks the path to full approval, representing a major positive catalyst for the stock.